Breaking News Instant updates and real-time market news.

ORCL

Oracle

$44.53

0.34 (0.77%)

, FB

Facebook

$143.80

1.53 (1.08%)

06:26
04/21/17
04/21
06:26
04/21/17
06:26

Oracle to pay over $850M for Moat, Recode says

Oracle (ORCL) is acquiring digital ad tracker Moat for more than $850M, Recode reports, citing a person familiar with the deal. When the deal closes, Moat will operate as an independent unit offered as part of Oracle's "data cloud" suite of products. Both Facebook (FB) and Google (GOOG, GOOGL) allow Moat to check in on advertisements that run on their platforms and "Google's YouTube recently announced that it would work with Moat to help advertisers verify that their messages aren't running next to offensive videos," according to Recode. Reference Link

ORCL

Oracle

$44.53

0.34 (0.77%)

FB

Facebook

$143.80

1.53 (1.08%)

GOOG

Alphabet

$841.65

3.44 (0.41%)

GOOGL

Alphabet Class A

$860.08

3.57 (0.42%)

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 22

    May

ORCL Oracle
$44.53

0.34 (0.77%)

03/16/17
BERN
03/16/17
NO CHANGE
BERN
Oracle 'continuing to turn the corner,' says Bernstein
After Oracle reported stronger than expected Q3 results, Bernstein analyst Mark Moerdler says that the company "is continuing to turn the corner." The analyst notes that the average rate of return of the company's organic cloud bookings growth came in at 50%-60%. He is impressed by this metric and believes that the company is "continuing to turn the corner," driven by its cloud business. Moerdler expects the company's multiple to expand going forward and he keeps an Outperform rating on the shares.
03/16/17
03/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Oracle (ORCL) was upgraded to Market Perform from Underperform at JMP Securities and to Overweight from Neutral at JPMorgan. 2. GoPro (GPRO) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the recent stabilization in revenue as well as the company's "significant" restructuring initiatives accelerate its path to profitability to 2017 from 2019. These developments should, at the very least, stave off the bear scenario for a few quarters, Kovler tells investors in a research note. He raised his price target for GoPro shares to $9 from $8. 2. TJX (TJX) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Fassler saying the company offers long-term secular growth along with near-term catalysts. The analyst expects TJX to grow market share at the expense of department stores. 4. Inovio (INO) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy saying it has multiple earlier stage programs moving forward with more significant data points coming in 2017 while it moves closer to its pivotal study in cervical dysplasia. He notes that his model assumes that VGX-3100 is commercialized in 2021 for cervical dysplasia. 5. Quest Diagnostics (DGX) upgraded to Neutral from Underperform at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/17
BARD
03/28/17
NO CHANGE
BARD
Accenture unlikely to be bought by Oracle, says Baird
Baird said reports that Oracle (ORCL) may purchase Accenture (ACN) is unlikely given Accenture is known for being software agnostic and its a people based business. The firm's analyst views Accenture risk/reward as balanced but said 2H 2017 is improving as comps ease and cyclical end markets do better.
03/29/17
WEDB
03/29/17
NO CHANGE
Target $43
WEDB
Neutral
Wedbush does not see Oracle moving forward with Accenture
Wedbush analyst Steve Koenig says he's skeptical that The Register's report of Oracle (ORCL) performing due diligence on a potential acquisition of Accenture (ACN) will progress very far. Look beyond Accenture for potential acquisition targets, Koenig tells investors in a research note. The analyst thinks more interesting targets lie elsewhere, including vendors such as health care specialists athenahealth (ATHN) and Veeva Systems (VEEV). He reiterates a Neutral rating on Oracle with a $43 price target.
FB Facebook
$143.80

1.53 (1.08%)

04/17/17
JEFF
04/17/17
NO CHANGE
Target $30
JEFF
Buy
Jefferies sees potential upside to Snap's Q1 results after survey
After surveying 1,000 internet users in the U.S. aged 18-45 who use both Facebook (FB) and Snap's (SNAP) Snapchat, Jefferies analyst Brian Fitzgerald believes there could be upside to Snap's Q1 results. The survey found that both Instagram and Snapchat are seeing continued user growth, with Snapchat usage growing fastest among the older demographic, Fitzgerald tells investors in a research note. The analyst also believes Snap's recent improvements to targeting and the increase gamified ad formats will help drive average revenue per user growth over time. Fitzgerald keeps a Buy rating on Snap with a $30 price target. The stock closed Thursday down 1c to $20.19.
04/17/17
FBCO
04/17/17
NO CHANGE
Target $175
FBCO
Outperform
Facebook price target raised to $175 from $170 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Facebook to $175 from $170 ahead of Q1 results, and as he increases his ad volume growth estimates for 2H17 from what he felt was "an excessively conservative" level, offset by higher anticipated content spend. The analyst reiterates an Outperform rating on the shares.
04/17/17
AGIS
04/17/17
NO CHANGE
Target $160
AGIS
Buy
Facebook price target raised to $160 ahead of F8, earnings at Aegis
Aegis analyst Victor Anthony said he expects Facebook's annual "F8" developer conference this week and the company's Q1 earnings report on May 3 to both be catalysts for the stock and raised his price target on the shares to $160 from $155 ahead of the events. He expects F8 to focus on innovations with the camera and video and he predicts the company will report solid quarterly results given strong advertiser checks. Anthony keeps a Buy rating on Facebook shares.
04/19/17
MSCN
04/19/17
NO CHANGE
MSCN
Facebook overall trends remain 'very strong,' says MScience
MScience analyst Steven Weinstein is forecasting Facebook's North American revenues of 4.07B, down slightly from $4.08B, above consensus of $4.005B. The analyst said slowing increases in US spending per advertiser led to a modest deceleration in revenue growth, but these trends are reflected in management's comments regarding ad load leveling off. Weinstein views overall trends as "very strong."
GOOG Alphabet
$841.65

3.44 (0.41%)

04/12/17
JMPS
04/12/17
NO CHANGE
JMPS
MINDBODY partnership positive, says JMP Securities
JMP Securities analyst Patrick Walravens says that MINDBODY's (MB) partnership with Google (GOOG, GOOGL) will enable MINDBODY's subscribers "to use dynamic pricing," and allow the company to increase its revenue by charging subscribers "a 10% fee for the booking and a 1% fee for the payment processing." The analyst keeps a $32 price target and an Outperform rating on MINDBODY.
04/11/17
04/11/17
UPGRADE
Target $43

Overweight
Yelp upgraded to Overweight on 'underappreciated core' at Pacific Crest
As previously reported, Pacific Crest analyst Brad Erickson upgraded Yelp (YELP) to Overweight from Sector Weight, saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG) and Facebook (FB). Over $60B of offline local ad spending is shifting toward online and Yelp remains well-positioned to capitalize on this trend, though its core business is underappreciated in the shares' current value, said Erickson, who has a $43 price target on the stock.
04/17/17
FBCO
04/17/17
NO CHANGE
Target $1100
FBCO
Outperform
Credit Suisse remains bullish on Alphabet ahead of Q1 results
Credit Suisse analyst Stephen Ju notes that Alphabet's shares have underperformed relative to its Internet large cap peers in 2016 and 2017 year to date. Nonetheless, he points out that even as the sheer size of its search business continues to blunt the contributions from other businesses, YouTube, Play, and Cloud collectively should be contributing about 1/3 of Net Revenue within three years. Further, the analyst anticipates free cash flow to grow at about 17.5% CAGR over the next five years, and therefore argues that Alphabet Class A shares should trade higher. Ju reiterates an Outperform rating and $1100 price target on the shares.
04/13/17
COWN
04/13/17
NO CHANGE
Target $60
COWN
Outperform
Criteo price target raised to $60 from $55 at Cowen
Cowen analyst Thomas Champion raised his price target on Criteo (CRTO) to $60 from $55 as he believes the company is well positioned in the near term given recent AdTech moves by Facebook (FB) and Alphabet (GOOG). He sees header bidding adoption as opening more inventory and sees the long-term potential for more competition. Champion raised his estimates to account for the seasonal impact in revenues versus more linear growth in expenses while reiterating his Outperform rating on Criteo shares.
GOOGL Alphabet Class A
$860.08

3.57 (0.42%)

04/20/17
PACS
04/20/17
NO CHANGE
PACS
Alphabet checks positive, says Pacific Crest
Checks with advertisers indicate that "search remains very strong" for Alphabet, while advertisers' feedback on YouTube "remained very positive," according to Pacific Crest analyst Andy Hargreaves. He keeps a $1,040 price target on the shares and recommends buying the stock.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

RGEN

Repligen

$35.06

-0.78 (-2.18%)

19:19
04/21/17
04/21
19:19
04/21/17
19:19
Initiation
Repligen initiated at First Analysis »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 30

    May

  • 06

    Jun

TWTR

Twitter

$14.63

-0.02 (-0.14%)

18:07
04/21/17
04/21
18:07
04/21/17
18:07
Periodicals
Homeland Security investigates potential abuse in Twitter case, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

17:46
04/21/17
04/21
17:46
04/21/17
17:46
Periodicals
Waymo:Uber misled court on Levandowski using LIDAR secrets, Bloomberg says »

According to Bloomberg,…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
CareDx receives expected letter from Nasdaq »

CareDx announced that, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$44.45

-0.2 (-0.45%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
Greenbrier CEO intends to sell one-half of his position in company stock »

The CEO of The Greenbrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx backs FY17 revenue view $45M-$50M, consensus $47.62M »

Revenue view excludes any…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx reports Q4 adjusted EPS (13c), consensus (18c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$1.69

-0.05 (-2.87%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Hot Stocks
Alliance MMA announces shareholder filed lawsuit against the company »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:30
04/21/17
04/21
17:30
04/21/17
17:30
Hot Stocks
CareDx names Michael Bell CFO »

CareDx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

, XOMA

XOMA

$7.73

0.26 (3.48%)

17:22
04/21/17
04/21
17:22
04/21/17
17:22
Hot Stocks
Novo Nordisk terminates exclusive license agreement with XOMA »

On April 20, XOMA (XOMA)…

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

XOMA

XOMA

$7.73

0.26 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 18

    May

  • 06

    Jun

HH

Hooper Holmes

$0.72

-0.1973 (-21.44%)

17:21
04/21/17
04/21
17:21
04/21/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Hooper Holmes »

John Pappajohn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$28.00

0.15 (0.54%)

17:14
04/21/17
04/21
17:14
04/21/17
17:14
Earnings
First Bancshares reports Q1 EPS 12 c with items, consensus 35c »

Reports Q1 provision for …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRWI

DragonWave

$1.23

-0.025 (-2.00%)

17:04
04/21/17
04/21
17:04
04/21/17
17:04
Hot Stocks
DragonWave did not regain compliance with Nasdaq listing standards »

DragonWave announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:02
04/21/17
04/21
17:02
04/21/17
17:02
Hot Stocks
Sears establishes special committee to market certain real estate properties »

Sears Holdings said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
Sears names Rob Riecker CFO »

Sears announced that Rob…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

UAL

United Continental

$69.56

-0.24 (-0.34%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
UAL: employee incentive opportunity to be tied to 'customer experience' »

United Continental said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Earnings
Sears sees FY17 net income $185M-$285M »

"The retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

16:59
04/21/17
04/21
16:59
04/21/17
16:59
Hot Stocks
Sears raises annualized cost savings target to $1.25B from $1B »

Sears Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

LTBR

Lightbridge

$1.25

-0.06 (-4.58%)

16:51
04/21/17
04/21
16:51
04/21/17
16:51
Hot Stocks
CEO of Lightbridge Seth Grae reports 5.1% stake in company »

As of March 22, Seth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46
Syndicate
Breaking Syndicate news story on Ionis Pharmaceuticals »

Ionis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.